CONCORDBIO

Concord Biotech Share Price

₹2,117.60 -42.85 (-1.98%)

22 Jan, 2025 12:32

SIP TrendupStart SIP in CONCORDBIO

Start SIP

Performance

  • Low
  • ₹2,095
  • High
  • ₹2,164
  • 52 Week Low
  • ₹1,327
  • 52 Week High
  • ₹2,664
  • Open Price₹2,160
  • Previous Close₹2,160
  • Volume31,772

Investment Returns

  • Over 1 Month -0.55%
  • Over 3 Month + 8.31%
  • Over 6 Month + 26.61%
  • Over 1 Year + 51.8%
SIP Lightning

Smart Investing Starts Here Start SIP with Concord Biotech for Steady Growth!

Invest Now

Concord Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 67.6
  • PEG Ratio
  • 8.7
  • Market Cap Cr
  • 22,154
  • P/B Ratio
  • 13.9
  • Average True Range
  • 97.06
  • EPS
  • 31.35
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 37.97
  • RSI
  • 48.08
  • MFI
  • 58.65

Concord Biotech Financials

Concord Biotech Technicals

EMA & SMA

Current Price
₹2,117.60
-42.85 (-1.98%)
pointer
  • stock-down_img
  • Bearish Moving Average 10
  • stock-up_img
  • Bullish Moving Average 6
  • 20 Day
  • ₹2,195.61
  • 50 Day
  • ₹2,124.10
  • 100 Day
  • ₹2,014.71
  • 200 Day
  • ₹1,836.18

Resistance and Support

2179.1 Pivot Speed
  • R3 2,285.05
  • R2 2,255.95
  • R1 2,208.20
  • S1 2,131.35
  • S2 2,102.25
  • S3 2,054.50

What's your outlook on Concord Biotech?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Concord Biotech Limited is an R&D-driven biopharma company with two API units and one formulation unit in Gujarat, India. The company supplies APIs and finished formulations across 70+ countries, including the USA, Europe, Japan, and India.

Concord Biotech Ltd has an operating revenue of Rs. 1,085.75 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 40% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 20% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 10% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Concord Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results
2024-08-09 Quarterly Results
2024-05-23 Audited Results & Dividend
2024-02-08 Quarterly Results
2023-11-08 Quarterly Results
Date Purpose Remarks
2024-06-22 FINAL Rs.8.75 per share(875%)Dividend
View More

Concord Biotech F&O

Concord Biotech Shareholding Pattern

44.08%
4.97%
4.3%
8.1%
7.33%
31.22%

About Concord Biotech

  • NSE Symbol
  • CONCORDBIO
  • BSE Symbol
  • 543960
  • Chairman & Managing Director
  • Mr. Sudhir Vaid
  • ISIN
  • INE338H01029

Similar Stocks to Concord Biotech

Concord Biotech FAQs

Concord Biotech share price is ₹2,117 As on 22 January, 2025 | 12:18

The Market Cap of Concord Biotech is ₹22153.5 Cr As on 22 January, 2025 | 12:18

The P/E ratio of Concord Biotech is 67.6 As on 22 January, 2025 | 12:18

The PB ratio of Concord Biotech is 13.9 As on 22 January, 2025 | 12:18

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23